Kaplan–Meier survival analyses were performed in subgroups to exclude the bias of imbalance of T stage, expectedly, patients with elevated sc-Src had worse 9-year cancer-specific survival (CSS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and bone metastasis-free survival (bone-MFS) (Figure 1B–1E) compared with sc-Src-low patients in the T = 3/4 subgroup, with no significant difference in the baseline clinical characteristics (Supplementary Table S2). This evidence concerns the gene SRC and cancer.